Streetbeat News

Regulatory

TTOO

T2 Biosystems, Inc. (NASDAQ:TTOO) shares fell in after-hours trading following the company's announcement of preliminary Q3 results. The company reported a 60% decrease in total revenue compared to the same period last year, mainly due to a $1.0 million decline in BARDA revenue. The company also announced FDA 510(k) clearance for the T2Biothreat Panel and 510(k) submission for Acinetobacter baumannii detection. The stock price drop follows a 43.9% decrease during regular trading due to a reverse stock split.

Portfolio Pulse from Ryan Gustafson

October 12, 2023 | 8:46 pm

PSQH

PSQ Holdings, Inc. (NYSE:PSQH) announced that the SEC has declared the company's resale registration statement on Form S-1 effective. The Form S-1 does not register any new or additional securities, but shares issuable upon exercise of existing warrants. The shares and warrants registered for resale were issued in connection with the company's business combination with Colombier Acquisition Corp.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:44 pm

PANL

Pangaea Logistics Solutions Ltd. (NASDAQ:PANL) announced that its dry bulk carrier, Nordic Nuluujaak, has been awarded the Class Silent (E) Notation by DNV, making it the first dry bulk carrier to receive this certification. The Silent (E) Notation is given to vessels that can effectively reduce environmental noise emissions. The company's CEO, Mark Filanowski, emphasized the importance of reducing ecological impact, including underwater noise.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:41 pm

SGHT

Sight Sciences, Inc. (NASDAQ:SGHT) has announced the full phase I results from the SAHARA randomized controlled trial, demonstrating that TearCare technology was superior to Restasis prescription eyedrops for the treatment of dry eye disease. The study included 345 subjects at 25 sites in 14 states. The results are expected to be published in a peer-reviewed journal in late 2023.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:37 pm

IMRX

Immuneering Corporation (NASDAQ:IMRX) presented encouraging preclinical data for IMM-1-104 and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including models of RAS and RAF mutant melanoma, pancreatic cancer, and lung cancer. The company believes that IMM-1-104 and IMM-6-415, alone, and in combination with other agents, have the potential to bring significant benefit to broad populations of patients with RAS or RAF mutant cancers.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:36 pm

RANI

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announced it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research. The presentation will detail the daily administration of an oral robotic pill (RT-102) that safely and reliably delivers Teriparatide with high bioavailability in women volunteers, based on a Phase I study.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:35 pm

OM

Outset Medical, Inc. (NASDAQ:OM) reported preliminary Q3 2023 financial results, with revenue of $30.4M, a 9% increase YoY. The company's total cash, including restricted cash, cash equivalents, and short-term investments, was $197M as of Sept. 30, 2023. However, growth in the quarter was affected by the recent FDA warning letter and a cautious outlook on capital spending. The company remains confident about generating sustained long-term growth and reaching profitability.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:34 pm

CERE

Cerevel Therapeutics Holdings has filed a prospectus supplement with the SEC, relating to the offering of 19.7 million shares of the company's common stock.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:27 pm

TGL

Treasure Global Inc has received a notice from Nasdaq stating that it is no longer in compliance with the minimum stockholders' equity requirement, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:25 pm

MGAM

Mobile Global eSports has not regained compliance with Nasdaq's minimum bid price requirement. Nasdaq has given the company an additional 180 days, until April 8, 2024, to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:24 pm